The OlympiAD clinical trial randomly assigned patients with advanced HER2-negative breast cancer and a germlineBRCA mutation to a PARP inhibitor, olaparib (300 mg twice daily), or standard physician’s choice chemotherapy59. The gene discussed is ERBB2; the disease is breast carcinoma.